No Data
No Data
Zhejiang Hisoar Pharmaceutical (002099.SZ): As of June 20th, the number of shareholders in the company is 28,949.
On June 25th, Gelonhui reported that as of June 20th, the number of shareholders in Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) was 28,949 on their investor interaction platform.
Pinning Down Zhejiang Hisoar Pharmaceutical Co., Ltd.'s (SZSE:002099) P/S Is Difficult Right Now
When you see that almost half of the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 3.1x, Zhejiang Hisoar Pharmaceutical Co., Ltd. (SZSE:002099) looks t
Health Check: How Prudently Does Zhejiang Hisoar Pharmaceutical (SZSE:002099) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when
Haixiang Pharmaceutical (002099.SZ): Currently, the hedging ratio continues to remain low, and the impact on the company's future performance will decrease
Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company's foreign export business is high, and the main purpose of the company hedging a certain percentage of US dollar assets is to reduce the uncertain impact of large exchange rate fluctuations and improve the company's resilience to risks. Currently, the hedging ratio continues to remain low, and the impact on the company's future performance will decrease.
Haixiang Pharmaceutical (002099.SZ): The company will not build a large-scale sales team in pharmaceutical-side sales
Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Sheet shows that the company will not build a large-scale sales team in pharmaceutical-side sales, and will mainly expand market sales by participating in collection and cooperating with other sales companies. The company successfully won the bid for the ninth batch of voglevosaccharide tablets approved last year. Supply has already begun this year, and sales markets outside of collection are also being developed simultaneously. Pantoprazole sodium enteric tablets, which passed the consistency evaluation last year, are also on sale, and this year's formulation revenue should increase by magnitude. In addition, reglinide tablets are in the supplementation phase, and a total of 5 hypoglycemic and psychotropic products are being developed
Haixiang Pharmaceutical (002099.SZ): Currently, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum
Gelonghui, May 21丨Haixiang Pharmaceutical (002099.SZ) Investor Relations Activity Record Form shows that the company set up a new major customer department, and the chairman personally led the team to connect with potential customers to dig deeper into strategic customer project cooperation. At the same time, it quickly responds to customer needs with the company's own advantages such as quality system, process optimization ability, and commercial large-scale production capacity, and provides strong support for customer project registration and certification, and achieve rapid commercial implementation of the project. At present, the company's CMO/CDMO business strategic customer stock business maintains a good growth momentum, and new strategic customer projects continue to advance
No Data